TransCode Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 536.81% HC Wainwright & Co. → $3 Reiterates Buy → Buy 04/03/2024 536.81% HC Wainwright & Co. →

BenzingaApr 16 22:49

TransCode Therapeutics: A Promising Oncology Investment With FDA-Backed Clinical Advancements

TipRanksApr 16 00:35

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial With TTX-MC138 In Patients With Advanced Solid Tumors

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial With TTX-MC138 In Patients With Advanced Solid Tumors

BenzingaApr 15 21:03

Promising Phase 0 Results and Upcoming Trial Boost Confidence in TransCode Therapeutics

TipRanksApr 4 00:05

HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics with a Buy and maintains $3 price target.

Analyst UpgradesApr 4 00:03

TransCode Therapeutics Reports FY Results

Seeking AlphaApr 3 22:29